Ropes & Gray represented the underwriters in Rhythm Pharmaceuticals’ (Nasdaq: RYTM) $201 million equity offering, including the full exercise of the underwriters’ $26 million option to purchase additional shares. The transaction closed on July 11.
Rhythm is a global commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases.
The team was led by capital markets partners Tom Danielski and Tristan VanDeventer.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.

